Antimicrobial Susceptibility Testing MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy Test Method / TechnologyBy Organism Type TestedBy ApplicationBy Sample/specimen TypeBy End UserBy Testing Site / Care SettingBy Distribution ChannelBy Testing Standard / Breakpoint Guideline

Antimicrobial susceptibility testing covers the instruments, reagents, consumables and software used to determine which antibiotics, antifungals, antivirals or antiparasitic agents will inhibit a specific pathogen isolated from a patient or environmental sample. It spans manual phenotypic methods such as disk diffusion and broth microdilution, automated instrument platforms, and genotypic methods that detect resistance genes directly, along with the data management systems that report results back into a laboratory or hospital record system. Buyers include hospital and reference clinical laboratories, public health and surveillance agencies, pharmaceutical and biotechnology developers testing new antimicrobial candidates, and food, water and veterinary testing laboratories.

Between 2025 and 2034 the global antimicrobial susceptibility testing market moves from USD 4.65 billion to USD 9.68 billion, compounding at 8.5% a year. Fifteen years are covered in all, taking in USD 3.19 billion in 2020, USD 4.31 billion in 2024, USD 5.04 billion in 2026 and USD 6.99 billion in 2030.

The product type mix shifts over the period. Reagents & Consumables is the largest line in 2025 at USD 1.77 billion, a 38.1% share, moving to USD 3.48 billion and 36% by 2034. Software & Data Management Systems grows fastest at 13.7%, taking its share from 4.7% to 8.1%, while Manual & Non-Automated Instruments (Incubators, Readers) grows slowest at 3.6%. Automated & Semi-Automated AST Instruments, Software & Data Management Systems and Testing Services take share over the period; Reagents & Consumables and Manual & Non-Automated Instruments (Incubators, Readers) give it up while still growing in absolute terms.

Cut by test method / technology, the largest line is Automated Broth Microdilution Systems: 24.1% of 2025 revenue, worth USD 1.12 billion, and 25% at USD 2.42 billion by 2034. Genotypic / Molecular AST grows faster at 12.9% against 9%, moving from 14% of revenue to 20% by 2034. Both this axis and the product type one divide the same revenue, which is why they are alternative views, not components.

The regional order runs from North America at 40.2% of 2025 revenue down to Middle East and Africa at 3.7%. North America is worth USD 1.87 billion in 2025 and USD 3.4 billion in 2034; Europe, second at 26%, moves from USD 1.21 billion to USD 2.32 billion. Share shifts toward Asia Pacific and Latin America over the forecast period, so the regional split repays a close reading.

Coverage extends to five regions, five product type lines and nine segmentation axes over the full fifteen years. The 2025 total itself is triangulated from published sources and category proxies, with no independently sourced count behind it, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• Revenue grows from USD 4.65 billion in 2025 to USD 9.68 billion in 2034, a compound annual rate of 8.5%, having reached USD 4.31 billion in 2024 from USD 3.19 billion in 2020.
• The largest line by product type is Reagents & Consumables, worth USD 1.77 billion and 38.1% of revenue in 2025, rising to USD 3.48 billion and 36% by 2034.
• Fastest growth on the product type axis belongs to Software & Data Management Systems: 13.7% a year, USD 0.22 billion to USD 0.78 billion, and a share moving from 4.7% to 8.1%.
• The bull case puts 2034 revenue at USD 10.84 billion and the bear case at USD 8.52 billion, either side of the USD 9.68 billion base case, each with its own stated assumption in the full report.
• North America holds 40.2% of global revenue in 2025 at USD 1.87 billion, the largest of the five regions tracked, and reaches USD 3.4 billion by 2034.
• 86.6% of North America's base-year revenue comes from the United States alone: USD 1.62 billion in 2025, rising to USD 2.96 billion by 2034, which is why it is that region's worked example.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

The global antimicrobial susceptibility testing market is shaped over 2026-2034 by three measurable movements: a change in the product type mix, a shift in where revenue sits geographically, and the 8.5% rate carrying the total.

All three are changes in mix, not in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.

Software & Data Management Systems grows at more than twice the pace of Manual & Non-Automated Instruments (Incubators, Readers). 13.7% against 3.6%: that gap, between Software & Data Management Systems and Manual & Non-Automated Instruments (Incubators, Readers), is the largest on the product type axis. Software & Data Management Systems takes its share of revenue from 4.7% to 8.1% while Manual & Non-Automated Instruments (Incubators, Readers) gives up ground, from 12% to 8%. Neither contracts: USD 0.22 billion becomes USD 0.78 billion, USD 0.56 billion becomes USD 0.77 billion. What the spread decides is which of them a supplier's revenue is exposed to.

Growth concentrates in Asia Pacific and Latin America. Asia Pacific moves from 24.7% of revenue in 2025 to 31.8% in 2034, worth USD 1.15 billion rising to USD 3.08 billion; Latin America moves from 5.4% of revenue in 2025 to 5.5% in 2034, worth USD 0.25 billion rising to USD 0.53 billion. Against that, North America at 40.2% moving to 35.1%, Europe at 26% moving to 24%, Middle East and Africa at 3.7% moving to 3.6%, a fall in share, not in revenue. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

Fifteen years without a discontinuity. Year by year the total runs USD 3.19 billion in 2020, USD 4.31 billion in 2024, USD 4.65 billion in 2025, USD 5.04 billion in 2026, USD 6.99 billion in 2030 and USD 9.68 billion in 2034. Against 7.83% through the historical period, the 8.5% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the product type and regional axes, not by the headline rate.

The fastest line decides the blended rate

Growth in the global antimicrobial susceptibility testing market comes from three measurable sources over 2026-2034: the market's own compounding at 8.5%, the share gained by faster-growing product type lines, and expansion in the regions taking a larger part of global revenue.

What holds the forecast back

Upside case: USD 10.84 billion by 2034

One product type line carries the market

In North America, 40.2% of global revenue puts 2025 at USD 1.87 billion on the way to USD 3.4 billion by 2034. It is a dominant region on this axis, first by revenue throughout the period.

Its share moves to 35.1% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The product type mix reported at global level applies here, with Reagents & Consumables the largest line at 38.1% of 2025 revenue and Software & Data Management Systems the fastest-growing at 13.7%. The full report breaks North America out along every axis and by country.

86.6% of North America's base-year revenue comes from the United States; USD 1.62 billion, rising to USD 2.96 billion by 2034. Carrying 86.6% of the region in the base year, it sets North America's direction instead of merely contributing to it. The region itself runs USD 1.87 billion to USD 3.4 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in the United States follows the product type mix reported at global level: Reagents & Consumables is the largest line at 38.1% of 2025 revenue, moving to 36% by 2034, while Software & Data Management Systems grows fastest at 13.7% and takes its share from 4.7% to 8.1%. Its 86.6% weight in North America means those movements carry straight into the regional totals. Revenue by product type for the United States is reported separately in the full report.

Antimicrobial susceptibility testing systems sold in the United States are regulated by the Food and Drug Administration as in vitro diagnostic devices. Most instruments and their associated panels, cards, or discs are cleared through the premarket notification pathway administered by the FDA's Center for Devices and Radiological Health, with breakpoint interpretations expected to align with recognized standards such as those published by the Clinical and Laboratory Standards Institute. Manufacturers must operate under a quality management system consistent with FDA requirements, maintain traceability of reagents and controls, and submit to establishment registration and device listing. Labelling must state intended use, specimen type, and performance characteristics established through clinical and analytical validation studies. Laboratories running these assays domestically also operate within the oversight of the Clinical Laboratory Improvement Amendments framework, which governs personnel qualifications and proficiency testing for the diagnostic category as a whole.

In the United States the field is bioMérieux SA, Becton, Dickinson and Company (BD), Danaher Corporation (Beckman Coulter / Cepheid), Remel / Oxoid (formerly Thermo Fisher Scientific Microbiology, now an independent Astorg portfolio company), Bruker Corporation, QIAGEN N.V., Accelerate Diagnostics, Inc., T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Merck KGaA (MilliporeSigma), Roche Diagnostics (F. Hoffmann-La Roche Ltd), Hardy Diagnostics, Liofilchem S.r.l., Alifax S.r.l., HiMedia Laboratories Pvt. Ltd., Creative Diagnostics, Selux Diagnostics, Inc., Autobio Diagnostics Co., Ltd., Werfen (Instrumentation Laboratory), Rapid Micro Biosystems, Inc., Diatron MI Zrt., Neogen Corporation, Abbott Laboratories and Coris BioConcept. Reagents & Consumables, at 38.1% of 2025 revenue, is where the volume sits, and Software & Data Management Systems, growing at 13.7%, is where position changes hands over the forecast period. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

Canada is sized at USD 0.22 billion in 2025, rising to USD 0.4 billion by 2034; 4.7% of global revenue and 11.8% of North America. It is reported separately from the United States across every segmentation axis in the full report.

Europe holds 26% of the global antimicrobial susceptibility testing market in 2025, worth USD 1.21 billion rising to USD 2.32 billion in 2034. It is a leading region on this axis, second by revenue throughout the period.

24% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Reagents & Consumables largest at 38.1% of 2025 revenue, Software & Data Management Systems fastest at 13.7%. Per-axis and per-country detail for Europe sits in the full report.

28.1% of Europe's base-year revenue comes from Germany; USD 0.34 billion, rising to USD 0.64 billion by 2034. Its 28.1% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 1.21 billion and USD 2.32 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

The product type pattern in Germany is the global one: 38.1% of 2025 revenue in Reagents & Consumables, 36% by 2034, against 13.7% growth in Software & Data Management Systems taking it from 4.7% to 8.1%. With 28.1% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-product type revenue for Germany appears on its own in the full report.

Antimicrobial susceptibility testing products placed on the German market fall under the EU In Vitro Diagnostic Regulation, which classifies devices by risk and assigns most susceptibility testing systems to a higher-risk category given their role in guiding antimicrobial therapy. Conformity is demonstrated through a notified body assessment and results in CE marking, supported by a technical file covering analytical performance, clinical evidence, and risk management. Manufacturers must appoint an authorized representative if based outside the European Union, register with the appropriate national authority, and comply with the German Medical Device Law, which implements the regulation domestically. Labelling and instructions for use must be provided in German and must specify intended use, limitations, and traceability to recognized reference methods such as those set by the European Committee on Antimicrobial Susceptibility Testing. Post-market surveillance obligations, including vigilance reporting, apply once a device is placed on the market.

The suppliers tracked in this study (bioMérieux SA, Becton, Dickinson and Company (BD), Danaher Corporation (Beckman Coulter / Cepheid), Remel / Oxoid (formerly Thermo Fisher Scientific Microbiology, now an independent Astorg portfolio company), Bruker Corporation, QIAGEN N.V., Accelerate Diagnostics, Inc., T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Merck KGaA (MilliporeSigma), Roche Diagnostics (F. Hoffmann-La Roche Ltd), Hardy Diagnostics, Liofilchem S.r.l., Alifax S.r.l., HiMedia Laboratories Pvt. Ltd., Creative Diagnostics, Selux Diagnostics, Inc., Autobio Diagnostics Co., Ltd., Werfen (Instrumentation Laboratory), Rapid Micro Biosystems, Inc., Diatron MI Zrt., Neogen Corporation, Abbott Laboratories and Coris BioConcept) compete in Germany across the product type lines above. Reagents & Consumables, at 38.1% of 2025 revenue, is where the volume sits, and Software & Data Management Systems, growing at 13.7%, is where position changes hands over the forecast period. The commercial size of that position is USD 1.21 billion in 2025 and USD 2.32 billion by 2034, 26% of the global total in the base year.

5.8% of global revenue is generated in the United Kingdom; USD 0.27 billion in 2025, reaching USD 0.51 billion in 2034, and 22.3% of Europe.

France is sized at USD 0.2 billion in 2025, rising to USD 0.38 billion by 2034; 4.3% of global revenue and 16.5% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

In Asia Pacific, 24.7% of global revenue puts 2025 at USD 1.15 billion and reaches USD 3.08 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.

31.8% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 8.5%; the revenue added here is disproportionate to where the region started.

The product type mix reported at global level applies here, with Reagents & Consumables the largest line at 38.1% of 2025 revenue and Software & Data Management Systems the fastest-growing at 13.7%. The full report breaks Asia Pacific out along every axis and by country.

China is the largest market within Asia Pacific, generating USD 0.52 billion in 2025 and projected to reach USD 1.4 billion by 2034. It accounts for 45.2% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 1.15 billion to USD 3.08 billion over the same period, and this is the market carrying the country-level detail in the full report.

China buys along the same lines as the market globally; Reagents & Consumables first at 38.1% of 2025 revenue and 36% in 2034, Software & Data Management Systems fastest at 13.7% on a share moving from 4.7% to 8.1%. With 45.2% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports China by product type separately.

In China, antimicrobial susceptibility testing instruments and reagents are regulated by the National Medical Products Administration as in vitro diagnostic reagents or devices, with classification determined by the risk the test result carries for clinical decision-making. Products in this category typically require registration review, supported by data on analytical performance, stability, and clinical agreement with an established reference method. Domestic manufacturers must hold a manufacturing licence, while imported products require a local agent to manage registration and post-market obligations. Labelling must be presented in Chinese, stating intended use, storage conditions, and traceability of calibration to recognized standards. Ongoing conformity is assessed against national standards issued by the Chinese standardization system for diagnostic reagents, and manufacturers must maintain a quality management system aligned with national good manufacturing practice requirements for medical devices, along with adverse event reporting once a product is on the market.

In China the field is bioMérieux SA, Becton, Dickinson and Company (BD), Danaher Corporation (Beckman Coulter / Cepheid), Remel / Oxoid (formerly Thermo Fisher Scientific Microbiology, now an independent Astorg portfolio company), Bruker Corporation, QIAGEN N.V., Accelerate Diagnostics, Inc., T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Merck KGaA (MilliporeSigma), Roche Diagnostics (F. Hoffmann-La Roche Ltd), Hardy Diagnostics, Liofilchem S.r.l., Alifax S.r.l., HiMedia Laboratories Pvt. Ltd., Creative Diagnostics, Selux Diagnostics, Inc., Autobio Diagnostics Co., Ltd., Werfen (Instrumentation Laboratory), Rapid Micro Biosystems, Inc., Diatron MI Zrt., Neogen Corporation, Abbott Laboratories and Coris BioConcept. The commercially relevant division is 38.1% of 2025 revenue in Reagents & Consumables, where the volume is, against 13.7% growth in Software & Data Management Systems, where share moves. The commercial size of that position is USD 1.15 billion in 2025, moving to USD 3.08 billion by 2034 across the forecast period.

Within Asia Pacific, Japan accounts for 20.9% of regional revenue and 5.2% of the global total, worth USD 0.24 billion in 2025 and USD 0.52 billion by 2034.

India is sized at USD 0.16 billion in 2025, rising to USD 0.46 billion by 2034; 3.4% of global revenue and 13.9% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

5.4% of the global antimicrobial susceptibility testing market sits in Latin America in 2025, worth USD 0.25 billion with USD 0.53 billion projected for 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Share climbs to 5.5% by 2034, on growth above the market's own 8.5%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The product type mix reported at global level applies here, with Reagents & Consumables the largest line at 38.1% of 2025 revenue and Software & Data Management Systems the fastest-growing at 13.7%. Per-axis and per-country detail for Latin America sits in the full report.

USD 0.14 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 0.3 billion by 2034. 56% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 0.25 billion in 2025 and USD 0.53 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Reagents & Consumables at 38.1% of 2025 revenue, easing to 36% by 2034, and the fastest is Software & Data Management Systems at 13.7%, from 4.7% to 8.1%. Its 56% weight in Latin America means those movements carry straight into the regional totals. The full report reports Brazil by product type separately.

Antimicrobial susceptibility testing products sold in Brazil are regulated by the National Health Surveillance Agency, which classifies in vitro diagnostic devices according to the risk they pose to patient management and requires registration before commercialization. Suppliers must demonstrate compliance with the agency's technical requirements for diagnostic performance, supported by data comparing results against a recognized reference methodology. A local technical responsible party or registration holder based in Brazil is required to manage the submission and to maintain contact with the regulator on quality and safety matters. Labelling must be presented in Portuguese and must disclose intended use, handling instructions, and expiry information. Manufacturing sites, whether domestic or foreign, are subject to good manufacturing practice inspection, and holders must comply with post-market vigilance obligations, including reporting of product complaints and safety issues to the agency.

In Brazil the field is bioMérieux SA, Becton, Dickinson and Company (BD), Danaher Corporation (Beckman Coulter / Cepheid), Remel / Oxoid (formerly Thermo Fisher Scientific Microbiology, now an independent Astorg portfolio company), Bruker Corporation, QIAGEN N.V., Accelerate Diagnostics, Inc., T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Merck KGaA (MilliporeSigma), Roche Diagnostics (F. Hoffmann-La Roche Ltd), Hardy Diagnostics, Liofilchem S.r.l., Alifax S.r.l., HiMedia Laboratories Pvt. Ltd., Creative Diagnostics, Selux Diagnostics, Inc., Autobio Diagnostics Co., Ltd., Werfen (Instrumentation Laboratory), Rapid Micro Biosystems, Inc., Diatron MI Zrt., Neogen Corporation, Abbott Laboratories and Coris BioConcept. Two different problems sit on the same axis: holding Reagents & Consumables at 38.1% of 2025 revenue, and taking Software & Data Management Systems while it grows at 13.7%. The commercial size of that position is USD 0.25 billion in 2025 and USD 0.53 billion by 2034, 5.4% of the global total in the base year.

Mexico is sized at USD 0.07 billion in 2025, rising to USD 0.15 billion by 2034; 1.5% of global revenue and 28% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

Middle East and Africa holds 3.7% of the global antimicrobial susceptibility testing market in 2025, worth USD 0.17 billion and reaches USD 0.35 billion by 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 3.6% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The product type mix reported at global level applies here, with Reagents & Consumables the largest line at 38.1% of 2025 revenue and Software & Data Management Systems the fastest-growing at 13.7%. Middle East and Africa is reported axis by axis and country by country in the full study.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.06 billion in 2025 and USD 0.125 billion in 2034. 35.3% of the region in the base year makes it the largest market here without making it the region. Set against USD 0.17 billion and USD 0.35 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Reagents & Consumables at 38.1% of 2025 revenue, easing to 36% by 2034, and the fastest is Software & Data Management Systems at 13.7%, from 4.7% to 8.1%. Its 35.3% weight in Middle East and Africa means those movements carry straight into the regional totals. The full report reports Saudi Arabia by product type separately.

In Saudi Arabia, antimicrobial susceptibility testing devices are regulated by the Saudi Food and Drug Authority under its medical device framework, which follows a risk-based classification broadly aligned with international in vitro diagnostic conventions. Placing a device on the market requires registration through the authority's electronic system, supported by evidence of conformity such as a valid certificate from a recognized international regulatory route and a declaration of conformity from the manufacturer. An authorized local representative or distributor is required to hold the registration and to liaise with the authority on regulatory matters. Labelling must appear in Arabic alongside the original language, stating intended use, storage conditions, and lot traceability. Establishments distributing these products must hold a valid medical device establishment licence, and the authority requires reporting of adverse events and field corrective actions once a device is in circulation.

Competition in Saudi Arabia runs between the suppliers this study tracks: bioMérieux SA, Becton, Dickinson and Company (BD), Danaher Corporation (Beckman Coulter / Cepheid), Remel / Oxoid (formerly Thermo Fisher Scientific Microbiology, now an independent Astorg portfolio company), Bruker Corporation, QIAGEN N.V., Accelerate Diagnostics, Inc., T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Merck KGaA (MilliporeSigma), Roche Diagnostics (F. Hoffmann-La Roche Ltd), Hardy Diagnostics, Liofilchem S.r.l., Alifax S.r.l., HiMedia Laboratories Pvt. Ltd., Creative Diagnostics, Selux Diagnostics, Inc., Autobio Diagnostics Co., Ltd., Werfen (Instrumentation Laboratory), Rapid Micro Biosystems, Inc., Diatron MI Zrt., Neogen Corporation, Abbott Laboratories and Coris BioConcept. Volume sits in Reagents & Consumables at 38.1% of 2025 revenue; movement sits in Software & Data Management Systems at 13.7% growth. The commercial size of that position is USD 0.17 billion in 2025, moving to USD 0.35 billion by 2034 across the forecast period.

Within Middle East and Africa, South Africa accounts for 23.5% of regional revenue and 0.86% of the global total, worth USD 0.04 billion in 2025 and USD 0.08 billion by 2034.

Download a free sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by product type, test method / technology, organism type tested, application, sample/specimen type, end user, testing site / care setting, distribution channel, testing standard / breakpoint guideline, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.